DDInter1843 DDInter364
Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Trandolapril {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Chlorpropamide (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound)
Trandolapril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Chlorpropamide (Compound)
Trandolapril (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Chlorpropamide (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Chlorpropamide (Compound)
Trandolapril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Glyburide (Compound) and Glyburide (Compound) resembles Chlorpropamide (Compound)
Trandolapril (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)